TNF and irritable bowel syndrome: TXYF attenuated postinfectious IBS symptom by attenuating behavioral hyperalgesia and antidiarrhea, mediated by inhibiting PAR-2 receptor expression, reducing the levels of SP, TNF-α, and IL-6 in colonic mucosa, and decreasing fecal serine protease activity[48].